Halozyme Therapeutics Inc. buy Morgan Stanley
Start price
26.12.23
/
50%
€34.03
Target price
26.12.24
€53.50
Performance (%)
17.72%
Price
10.05.24
€40.06
Summary
This prediction is currently active. The prediction currently has a performance of 17.72%. This prediction currently runs until 26.12.24. The prediction end date can be changed by Morgan_Stanley at any time. Morgan_Stanley has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Halozyme Therapeutics Inc. | 7.833% | 7.833% |
iShares Core DAX® | 4.094% | 4.888% |
iShares Nasdaq 100 | 1.424% | -0.445% |
iShares Nikkei 225® | -1.572% | -4.911% |
iShares S&P 500 | 1.822% | 0.776% |
Comments by Morgan_Stanley for this prediction
In the thread Halozyme Therapeutics Inc. diskutieren
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target lowered by analysts at Morgan Stanley from $61.00 to $59.00. They now have an "overweight" rating on the stock.
Ratings data for HALO provided by MarketBeat
Stopped prediction by Morgan_Stanley for Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc.
Start price
Target price
Perf. (%)
€40.11
10.08.23
10.08.23
€55.35
10.08.24
10.08.24
-0.12%
10.05.24
10.05.24
Halozyme Therapeutics Inc.
Start price
Target price
Perf. (%)
€42.50
06.03.23
06.03.23
€60.06
06.03.24
06.03.24
-10.61%
07.03.24
07.03.24